CN114870034A - 一种具备高效抗感染能力的基因转染纳米材料及其制备 - Google Patents
一种具备高效抗感染能力的基因转染纳米材料及其制备 Download PDFInfo
- Publication number
- CN114870034A CN114870034A CN202210145204.9A CN202210145204A CN114870034A CN 114870034 A CN114870034 A CN 114870034A CN 202210145204 A CN202210145204 A CN 202210145204A CN 114870034 A CN114870034 A CN 114870034A
- Authority
- CN
- China
- Prior art keywords
- infection
- gene
- nano material
- transfection
- gene transfection
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000012637 gene transfection Methods 0.000 title claims abstract description 45
- 239000002086 nanomaterial Substances 0.000 title claims abstract description 45
- 230000002924 anti-infective effect Effects 0.000 title claims abstract description 32
- 238000002360 preparation method Methods 0.000 title claims abstract description 10
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 28
- 208000015181 infectious disease Diseases 0.000 claims abstract description 15
- 238000011282 treatment Methods 0.000 claims abstract description 15
- 238000000034 method Methods 0.000 claims abstract description 14
- 239000002105 nanoparticle Substances 0.000 claims description 31
- 239000013612 plasmid Substances 0.000 claims description 29
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 24
- 239000003910 polypeptide antibiotic agent Substances 0.000 claims description 19
- 102100038608 Cathelicidin antimicrobial peptide Human genes 0.000 claims description 18
- 101000741320 Homo sapiens Cathelicidin antimicrobial peptide Proteins 0.000 claims description 18
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 16
- 229920001690 polydopamine Polymers 0.000 claims description 16
- 239000011248 coating agent Substances 0.000 claims description 8
- 238000000576 coating method Methods 0.000 claims description 8
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 claims description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 6
- 102000044503 Antimicrobial Peptides Human genes 0.000 claims description 5
- 108700042778 Antimicrobial Peptides Proteins 0.000 claims description 5
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 claims description 5
- LXBGSDVWAMZHDD-UHFFFAOYSA-N 2-methyl-1h-imidazole Chemical compound CC1=NC=CN1 LXBGSDVWAMZHDD-UHFFFAOYSA-N 0.000 claims description 4
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 claims description 4
- 229960003638 dopamine Drugs 0.000 claims description 4
- 239000012621 metal-organic framework Substances 0.000 claims description 4
- 238000003756 stirring Methods 0.000 claims description 4
- 108010002069 Defensins Proteins 0.000 claims description 3
- 102000000541 Defensins Human genes 0.000 claims description 3
- 238000011068 loading method Methods 0.000 claims description 3
- 239000000377 silicon dioxide Substances 0.000 claims description 3
- 238000002791 soaking Methods 0.000 claims description 3
- 238000005406 washing Methods 0.000 claims description 3
- 230000015572 biosynthetic process Effects 0.000 claims description 2
- 238000003786 synthesis reaction Methods 0.000 claims description 2
- 241000894006 Bacteria Species 0.000 abstract description 15
- 238000001890 transfection Methods 0.000 abstract description 15
- 201000010099 disease Diseases 0.000 abstract description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 9
- 230000000694 effects Effects 0.000 abstract description 9
- 230000003834 intracellular effect Effects 0.000 abstract description 4
- 230000008569 process Effects 0.000 abstract description 4
- 206010040872 skin infection Diseases 0.000 abstract description 4
- 238000010172 mouse model Methods 0.000 abstract description 3
- 230000001937 non-anti-biotic effect Effects 0.000 abstract description 3
- 238000011269 treatment regimen Methods 0.000 abstract description 2
- 150000001875 compounds Chemical class 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 26
- 239000000243 solution Substances 0.000 description 14
- 235000019441 ethanol Nutrition 0.000 description 4
- 239000007943 implant Substances 0.000 description 4
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 239000000975 dye Substances 0.000 description 3
- 230000005284 excitation Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- 239000011701 zinc Substances 0.000 description 3
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 210000003855 cell nucleus Anatomy 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 108700022109 ropocamptide Proteins 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- ONDPHDOFVYQSGI-UHFFFAOYSA-N zinc nitrate Chemical compound [Zn+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O ONDPHDOFVYQSGI-UHFFFAOYSA-N 0.000 description 2
- 238000010146 3D printing Methods 0.000 description 1
- YSWBFLWKAIRHEI-UHFFFAOYSA-N 4,5-dimethyl-1h-imidazole Chemical compound CC=1N=CNC=1C YSWBFLWKAIRHEI-UHFFFAOYSA-N 0.000 description 1
- 102100026887 Beta-defensin 103 Human genes 0.000 description 1
- 101710125298 Beta-defensin 2 Proteins 0.000 description 1
- 101710125296 Beta-defensin 3 Proteins 0.000 description 1
- 102100038326 Beta-defensin 4A Human genes 0.000 description 1
- 101710176951 Beta-defensin 4A Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 101150066002 GFP gene Proteins 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 210000004292 cytoskeleton Anatomy 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229960003085 meticillin Drugs 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 230000000399 orthopedic effect Effects 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 239000000304 virulence factor Substances 0.000 description 1
- 230000007923 virulence factor Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A61K38/1729—Cationic antimicrobial peptides, e.g. defensins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
- A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
- A61K47/6935—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Nanotechnology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Marine Sciences & Fisheries (AREA)
- Zoology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明涉及一种具备高效抗感染能力的基因转染纳米材料及其制备,纳米材料为负载质粒DNA的纳米颗粒,纳米颗粒的外层修饰有聚多巴胺涂层,并通过聚多巴胺涂层接枝抗菌肽。与现有技术相比,本发明构建的基因转染纳米材料具备优异的抗感染作用,可快速杀伤常见细菌;入胞能力较好,可有效杀伤进入细胞内部的胞内菌,更深入地清除隐蔽的难清除细菌;能够使目的基因转染效率明显提高,目的基因表达显著增加;在皮下感染小鼠模型治疗中,表现出更好的抗感染能力;可解决新兴治疗策略基因转染在感染相关疾病治疗中应用过程所面临的巨大挑战,有望为非抗生素的抗感染策略开辟新的方向,具有重大的社会、经济价值。
Description
技术领域
本发明属于基因转染技术领域,涉及一种具备高效抗感染能力的基因转染纳米材料及其制备。
背景技术
骨科植入物在临床上使用频率高,而植入物相关感染作为最常见且后果最严重的并发症之一,是临床上面临的一大难题。目前感染性疾病的治疗仍以抗生素为主,然而近年来,耐药菌的流行极大地削弱了抗生素的疗效;而另一方面,关于疗效更佳的新型抗生素研发遇到瓶颈。因此,非抗生素抗感染策略成为新的研究热点。
作为一种新兴技术,基因转染已得到广泛研究,在抗感染领域,具备抗感染能力的常见目的基因包括β-防御素2、β-防御素3、抗菌肽LL37等,成功转染后均表现出较好的抗感染作用。其中,常用的转染载体包括:1.病毒转染:腺病毒、慢病毒;2.非病毒转染:基因转染纳米平台。非病毒转染载体由于出色的转染效率、较高的生物安全性等优势,表现出优异前景。
基因转染治疗是否发挥疗效,取决于被转染的细胞能否顺利表达目标基因,而在感染环境中,细菌将从多方面影响细胞及周围组织的正常功能,使基因转染体系面临严峻挑战。首先,细菌可分泌多种毒性因子(如内毒素),直接杀伤周围细胞。细菌还可进入细胞内部形成胞内菌,诱导凋亡程序导致细胞死亡;也可与细胞长期共存,并存在杀死细胞并再次释放到胞外的可能性。因此,考虑到感染相关疾病的特殊性,即细菌影响细胞的正常功能甚至杀死细胞,存在进一步阻碍基因转染发挥治疗作用的可能性,上述现有基因转染技术均不能很好地适用于感染相关疾病的治疗。
发明内容
本发明的目的是针对现有基因转染方法在感染相关疾病治疗中面临的困境,提供一种具备高效抗感染能力的基因转染纳米材料及其制备。本发明中的纳米材料可作为非病毒纳米转染平台,同时实现快速杀菌及高效转染目的基因,改善基因转染方法在感染相关疾病中的应用前景。
本发明的目的可以通过以下技术方案来实现:
一种具备高效抗感染能力的基因转染纳米材料,该纳米材料为负载质粒DNA的纳米颗粒,所述的纳米颗粒的外层修饰有聚多巴胺涂层,并通过聚多巴胺涂层接枝抗菌肽。
进一步地,所述的质粒DNA为抗菌肽基因。
进一步地,所述的抗菌肽包括防御素、LL37或KR12中的一种。
进一步地,所述的纳米颗粒包括介孔二氧化硅或金属有机框架MOFs中的一种。
进一步地,在该纳米材料合成体系中,质粒DNA的含量为8-12μg/ml,聚多巴胺的含量为140-160mg/ml,抗菌肽的含量为8-12mg/ml。优选地,质粒DNA的含量为10μg/ml,聚多巴胺的含量为150mg/ml,抗菌肽的含量为10mg/ml。
一种具备高效抗感染能力的基因转染纳米材料的制备方法,该方法包括以下步骤:
1)将质粒DNA负载在纳米颗粒上,得到负载质粒DNA的纳米颗粒;
2)在步骤1)中得到的负载质粒DNA的纳米颗粒外包裹PDA并接枝抗菌肽;
3)经过后处理,得到所述的纳米材料。
进一步地,步骤1)具体为:步骤1)具体为:将Zn(NO3)与十六烷基三甲基溴化铵溶解在甲醇中得到溶液A,将LL37和2-甲基咪唑溶解在甲醇中得到溶液B,之后将溶液A与溶液B混合。
进一步地,步骤2)具体为:将多巴胺、负载质粒DNA的纳米颗粒、乙醇、三乙醇胺与LL37混合,之后室温下进行搅拌。
进一步地,搅拌时间为3-5小时,优选为4h。
进一步地,步骤3)中,后处理包括洗涤及浸泡。
例如,制备过程为:将2g Zn(NO3)·6H2O和0.15g十六烷基三甲基溴化铵(CTAB)溶解在10ml甲醇溶液中作为溶液A;将100μl LL37质粒(1000ng/ml)和0.34g 2-甲基咪唑溶解在10ml甲醇中形成溶液B,将溶液A与溶液B混合2小时。将0.15g多巴胺、10ml上述混合溶液、10ml乙醇、1.5ml三乙醇胺和10mg/ml的LL37混合,室温下搅拌4小时。之后用无水乙醇洗涤三次,再于20mL无水乙醇中浸泡三天。
目前,以介孔纳米颗粒负载质粒DNA为核心的非病毒基因转染体系,已被证明具备较高效的基因转染作用。本发明在此基础上进一步开发,目的是改善基因转染纳米平台的基因转染效率及抗感染能力。具体而言,本发明在纳米颗粒外层修饰聚多巴胺(PDA)涂层并接枝具备优异抗菌能力的抗菌肽。一方面,接枝的抗菌肽使此纳米材料具备了直接杀菌作用,包括直接清除微环境内的浮游细菌及已进入细胞内部的胞内菌,保证被转染目的基因的细胞不受到细菌的杀伤;另一方面,接枝的抗菌肽可进一步提高此基因转染体系的转染效率,包括增加纳米颗粒入胞、增加溶酶体逃逸等机制。
与现有技术相比,本发明具有以下特点:
1)本发明构建的基因转染纳米材料具备优异的抗感染作用,可快速杀伤MRSA(耐甲氧西林金黄色葡萄球菌)、E.coli(大肠杆菌)等常见细菌,例如,接枝LL37后对MRSA的杀菌率高达99.9%以上。
2)本发明构建的基因转染纳米材料入胞能力较好,可有效杀伤进入细胞内部的胞内菌,更深入地清除隐蔽的难清除细菌。
3)本发明构建的基因转染纳米材料能够使目的基因转染效率明显提高,目的基因表达显著增加。
4)本发明构建的基因转染纳米材料在皮下感染小鼠模型治疗中,表现出更好的抗感染能力。
5)本发明构建的基因转染纳米材料可解决新兴治疗策略基因转染在感染相关疾病治疗中应用过程所面临的巨大挑战,有望为非抗生素的抗感染策略开辟新的方向,具有重大的社会、经济价值。
附图说明
图1为实施例中生物安全性的结果图;
图2为实施例中材料入胞的共聚焦显微镜结果图;
图3为实施例中目的基因在MC3T3-E1细胞中转染表达的结果图;
图4为实施例中治疗皮下感染小鼠模型的结果图。
具体实施方式
下面结合附图和具体实施例对本发明进行详细说明。本实施例以本发明技术方案为前提进行实施,给出了详细的实施方式和具体的操作过程,但本发明的保护范围不限于下述的实施例。
本发明提供了一种具备高效抗感染能力的基因转染纳米材料,该纳米材料为负载质粒DNA的纳米颗粒,纳米颗粒的外层修饰有聚多巴胺涂层,并通过聚多巴胺涂层接枝抗菌肽。
其中,质粒DNA为抗菌肽基因。抗菌肽包括防御素、LL37或KR12中的一种。纳米颗粒包括介孔二氧化硅或金属有机框架中的一种。该纳米材料中,质粒DNA的含量为8-12μg/ml,聚多巴胺的含量为140-160mg/ml,抗菌肽的含量为8-12mg/ml。
本发明同时提供了上述基因转染纳米材料的制备方法,该方法包括以下步骤:
1)将质粒DNA负载在纳米颗粒上,得到负载质粒DNA的纳米颗粒;
2)在步骤1)中得到的负载质粒DNA的纳米颗粒外包裹PDA并接枝抗菌肽;
3)经过后处理,得到纳米材料。
步骤1)具体为:步骤1)具体为:将Zn(NO3)与十六烷基三甲基溴化铵溶解在甲醇中得到溶液A,将LL37和2-甲基咪唑溶解在甲醇中得到溶液B,之后将溶液A与溶液B混合。
步骤2)具体为:将多巴胺、负载质粒DNA的纳米颗粒、乙醇、三乙醇胺与LL37混合,之后室温下进行搅拌,搅拌时间为3-5小时。
步骤3)中,后处理包括洗涤及浸泡。
实施例:
本实施例提供了一种负载LL37质粒、并在外层制备PDA涂层并接枝LL37抗菌肽的ZIF8颗粒。研究发现,LL37@PDA-修饰后的基因转染纳米平台,在具备优异基因转染效果的同时,表现出良好的抗感染能力,可克服在感染相关疾病发生时,局部细胞所面临的细菌挑战,使新兴的基因治疗方式在感染相关疾病治疗中应用成为可能。
具体研究过程如下:
1、基因转染纳米材料的制备
将2g硝酸锌、0.34g二甲基咪唑、100μg LL37质粒在10ml乙醇中混合,通过一步法制备负载LL37质粒的ZIF8纳米颗粒,并进一步通过PDA涂层在纳米颗粒表面接枝LL37抗菌肽,最后将纳米颗粒离心收集,PBS清洗三遍后待用。
2、基因转染纳米材料的生物安全性检测
将MC3T3-E1细胞以每孔10000个的数量种于96孔板中,贴壁过夜后加入一定浓度上述制备的纳米材料,进一步孵育24小时后,利用CCK8检测各孔细胞活性情况。
图1为生物安全性结果图,图1显示了制得的基因转染纳米颗粒在1024ug/ml浓度下仍不具有明显的细胞毒性。
3、基因转染纳米材料的吞噬及目的基因转染检测
在上述制备的纳米材料表面吸附PI染料(红色,激发波长为535nm,发射波长为615nm),并与MC3T3-T1细胞孵育3h后,4%多聚甲醛固定,FITC(绿色,激发波长为488nm,发射波长为519nm)染细胞骨架,DAPI(蓝色,激发波长为358nm,发射波长为461nm)对细胞核进行染色。利用激光共聚焦显微镜观察材料的入胞情况。
设计的LL37质粒携带共同表达的GFP基因,即LL37质粒成功转染并被细胞表达后,细胞除了表达目的基因,还会自发表达GFP绿色荧光。利用纳米材料与MC3T3-T1细胞孵育36h后,4%多聚甲醛固定,DAPI对细胞核进行染色,并利用激光共聚焦显微镜对目的基因的表达情况进一步观察。
图2为材料入胞的共聚焦显微镜结果图,图2显示了基因转染纳米颗粒可大量入胞。
图3为目的基因在MC3T3-E1细胞中转染表达的结果图,图3显示了基因转染纳米颗粒入胞后进一步完成目的基因的转染,大量表达的GFP提示目的基因LL37也被大量表达。
4、基因转染纳米材料在小鼠皮下感染模型中的抗感染检测
将上述制备的基因转染纳米材料颗粒利用水凝胶负载于PCL/HA 3D打印支架中,并植入小鼠背部皮肤的皮下,同时加入50ul浓度为108CFUs/ml的MRSA构建皮下植入物相关感染模型。1周后观察对照组及实验组局部感染进展情况。
图4为治疗小鼠皮下植入物相关感染模型的结果图,图4显示了基因转染纳米颗粒在体内表现出显著的抗感染作用。
经过以上一系列实验,验证了本发明的基因转染纳米材料具有较好的抗感染能力,入胞能力优异,可高效转染目的基因,有望对现有的基因转染方法实现进一步改进,使其在感染相关性疾病的治疗应用中有更优的适用性。
上述的对实施例的描述是为便于该技术领域的普通技术人员能理解和使用发明。熟悉本领域技术的人员显然可以容易地对这些实施例做出各种修改,并把在此说明的一般原理应用到其他实施例中而不必经过创造性的劳动。因此,本发明不限于上述实施例,本领域技术人员根据本发明的揭示,不脱离本发明范畴所做出的改进和修改都应该在本发明的保护范围之内。
Claims (10)
1.一种具备高效抗感染能力的基因转染纳米材料,其特征在于,该纳米材料为负载质粒DNA的纳米颗粒,所述的纳米颗粒的外层修饰有聚多巴胺涂层,并通过聚多巴胺涂层接枝抗菌肽。
2.根据权利要求1所述的一种具备高效抗感染能力的基因转染纳米材料,其特征在于,所述的质粒DNA为抗菌肽基因。
3.根据权利要求2所述的一种具备高效抗感染能力的基因转染纳米材料,其特征在于,所述的抗菌肽包括防御素、LL37或KR12中的一种。
4.根据权利要求1所述的一种具备高效抗感染能力的基因转染纳米材料,其特征在于,所述的纳米颗粒包括介孔二氧化硅或金属有机框架中的一种。
5.根据权利要求1所述的一种具备高效抗感染能力的基因转染纳米材料,其特征在于,在该纳米材料合成体系中,质粒DNA的含量为8-12μg/ml,聚多巴胺的含量为140-160mg/ml,抗菌肽的含量为8-12mg/ml。
6.一种如权利要求1至5任一项所述的具备高效抗感染能力的基因转染纳米材料的制备方法,其特征在于,该方法包括以下步骤:
1)将质粒DNA负载在纳米颗粒上,得到负载质粒DNA的纳米颗粒;
2)在步骤1)中得到的负载质粒DNA的纳米颗粒外包裹PDA并接枝抗菌肽;
3)经过后处理,得到所述的纳米材料。
7.根据权利要求6所述的一种具备高效抗感染能力的基因转染纳米材料的制备方法,其特征在于,步骤1)具体为:将Zn(NO3)与十六烷基三甲基溴化铵溶解在甲醇中得到溶液A,将LL37和2-甲基咪唑溶解在甲醇中得到溶液B,之后将溶液A与溶液B混合。
8.根据权利要求6所述的一种具备高效抗感染能力的基因转染纳米材料的制备方法,其特征在于,步骤2)具体为:将多巴胺、负载质粒DNA的纳米颗粒、乙醇、三乙醇胺与LL37混合,之后室温下进行搅拌。
9.根据权利要求8所述的一种具备高效抗感染能力的基因转染纳米材料的制备方法,搅拌时间为3-5小时。
10.根据权利要求6所述的一种具备高效抗感染能力的基因转染纳米材料的制备方法,其特征在于,步骤3)中,后处理包括洗涤及浸泡。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210145204.9A CN114870034B (zh) | 2022-02-17 | 2022-02-17 | 一种具备高效抗感染能力的基因转染纳米材料及其制备 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210145204.9A CN114870034B (zh) | 2022-02-17 | 2022-02-17 | 一种具备高效抗感染能力的基因转染纳米材料及其制备 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114870034A true CN114870034A (zh) | 2022-08-09 |
CN114870034B CN114870034B (zh) | 2024-05-31 |
Family
ID=82666607
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210145204.9A Active CN114870034B (zh) | 2022-02-17 | 2022-02-17 | 一种具备高效抗感染能力的基因转染纳米材料及其制备 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114870034B (zh) |
Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2241312A1 (en) * | 2009-03-30 | 2010-10-20 | Isdin S.A. | Use of compositions comprising urea for treating microbial infections |
WO2012092849A1 (zh) * | 2011-01-04 | 2012-07-12 | 中国人民解放军总医院 | 聚酰胺-胺树枝状聚合物或其衍生物-math1基因纳米微粒及其治疗耳聋的应用 |
CN102719477A (zh) * | 2012-06-29 | 2012-10-10 | 兰州大学 | 基于n末端18烷酰化抗菌肽构建的非病毒基因载体 |
CN106333936A (zh) * | 2016-08-23 | 2017-01-18 | 浙江大学 | 一种载抗菌肽基因的药物递送系统及构建和应用 |
WO2017064687A1 (en) * | 2015-10-15 | 2017-04-20 | Centro De Neurociencias E Biologia Celular | A composition of gold nanoparticles having antimicrobial peptides bound on their surface for use the treatment of wound healing or in the treatment of ischemic or vascular diseases or in the treatment of skin disorders |
CN106581758A (zh) * | 2017-01-12 | 2017-04-26 | 广东泰宝医疗器械技术研究院有限公司 | 一种具诱导血管化能力的抗菌脱细胞真皮敷料及其制备方法 |
US20190224362A1 (en) * | 2018-01-19 | 2019-07-25 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Antimicrobial biopolymer compositions, methods of synthesis, and applications of use |
CN110464873A (zh) * | 2019-06-06 | 2019-11-19 | 重庆大学 | 具有消除表面生物膜功能的医用钛植入体的制备方法 |
CN110496229A (zh) * | 2019-09-16 | 2019-11-26 | 上海市肺科医院 | 一种具有缓释性的纳米颗粒包被的抗菌肽及其制备方法 |
CN111529682A (zh) * | 2020-05-11 | 2020-08-14 | 中国人民解放军陆军军医大学第一附属医院 | 一种趋化抗菌纳米材料及其制备方法和应用 |
CN111921514A (zh) * | 2020-07-28 | 2020-11-13 | 南通大学 | 一种具有抗菌性的TiO2与多孔碳纳米复合材料的制备方法 |
WO2021184500A1 (zh) * | 2020-03-20 | 2021-09-23 | 中国科学院动物研究所 | 一种表达ll-37多肽的重组表达载体、重组乳酸乳球菌、抗病毒药物及构建方法和应用 |
-
2022
- 2022-02-17 CN CN202210145204.9A patent/CN114870034B/zh active Active
Patent Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2241312A1 (en) * | 2009-03-30 | 2010-10-20 | Isdin S.A. | Use of compositions comprising urea for treating microbial infections |
WO2012092849A1 (zh) * | 2011-01-04 | 2012-07-12 | 中国人民解放军总医院 | 聚酰胺-胺树枝状聚合物或其衍生物-math1基因纳米微粒及其治疗耳聋的应用 |
CN102719477A (zh) * | 2012-06-29 | 2012-10-10 | 兰州大学 | 基于n末端18烷酰化抗菌肽构建的非病毒基因载体 |
WO2017064687A1 (en) * | 2015-10-15 | 2017-04-20 | Centro De Neurociencias E Biologia Celular | A composition of gold nanoparticles having antimicrobial peptides bound on their surface for use the treatment of wound healing or in the treatment of ischemic or vascular diseases or in the treatment of skin disorders |
CN106333936A (zh) * | 2016-08-23 | 2017-01-18 | 浙江大学 | 一种载抗菌肽基因的药物递送系统及构建和应用 |
CN106581758A (zh) * | 2017-01-12 | 2017-04-26 | 广东泰宝医疗器械技术研究院有限公司 | 一种具诱导血管化能力的抗菌脱细胞真皮敷料及其制备方法 |
US20190224362A1 (en) * | 2018-01-19 | 2019-07-25 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Antimicrobial biopolymer compositions, methods of synthesis, and applications of use |
CN110464873A (zh) * | 2019-06-06 | 2019-11-19 | 重庆大学 | 具有消除表面生物膜功能的医用钛植入体的制备方法 |
CN110496229A (zh) * | 2019-09-16 | 2019-11-26 | 上海市肺科医院 | 一种具有缓释性的纳米颗粒包被的抗菌肽及其制备方法 |
WO2021184500A1 (zh) * | 2020-03-20 | 2021-09-23 | 中国科学院动物研究所 | 一种表达ll-37多肽的重组表达载体、重组乳酸乳球菌、抗病毒药物及构建方法和应用 |
CN111529682A (zh) * | 2020-05-11 | 2020-08-14 | 中国人民解放军陆军军医大学第一附属医院 | 一种趋化抗菌纳米材料及其制备方法和应用 |
CN111921514A (zh) * | 2020-07-28 | 2020-11-13 | 南通大学 | 一种具有抗菌性的TiO2与多孔碳纳米复合材料的制备方法 |
Non-Patent Citations (7)
Title |
---|
SOMAYE RASHKI 等: "Delivery LL37 by chitosan nanoparticles for enhanced antibacterial and antibiofilm efficacy", CARBOHYDR POLYM, vol. 291, 1 September 2022 (2022-09-01), pages 119634 * |
XINHUA QU等: "Multi-Mode Antibacterial Strategies Enabled by Gene-Transfection and Immunomodulatory Nanoparticles in 3D-Printed Scaffolds for Synergistic Exogenous and Endogenous Treatment of Infections", ADVANCED MATERIALS, vol. 34, no. 18 * |
张旭冉: "LfcinB等抗菌肽原核和真核表达体系构建的初步研究", 中国优秀硕士学位论文全文数据库(电子期刊)基础科学辑, no. 7, 15 July 2020 (2020-07-15), pages 006 - 107 * |
李晖等: "基于构建抗感染骨科植入物的钛表面纳米化修饰和载药的不同方式", 上海交通大学学报(医学版), vol. 37, no. 6 * |
熊泰特等: "共表达猪IL-2与融合抗菌肽重组质粒 的构建及其小鼠免疫效应研究", 畜牧兽医科技信息, no. 3 * |
王淞等: "制备抗菌肽LL37修饰的金纳米颗粒及其体外转染和抗菌实验研究", 联勤军事医学, 6 November 2023 (2023-11-06), pages 725 - 730 * |
颜菖: "AuNPs@LL37/pDNAs复合物对糖尿病创面血管生成和创面愈合影响的研究", 中国优秀硕士学位论文全文数据库(电子期刊)医药卫生科技辑, no. 3 * |
Also Published As
Publication number | Publication date |
---|---|
CN114870034B (zh) | 2024-05-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Yuan et al. | Antibacterial surface design of biomedical titanium materials for orthopedic applications | |
Chen et al. | Synergistic chemotherapy and photodynamic therapy of endophthalmitis mediated by zeolitic imidazolate framework‐based drug delivery systems | |
Epple et al. | Application of calcium phosphate nanoparticles in biomedicine | |
Wiarachai et al. | Surface-quaternized chitosan particles as an alternative and effective organic antibacterial material | |
Zhang et al. | A multifunctional antibacterial coating on bone implants for osteosarcoma therapy and enhanced osteointegration | |
Qi et al. | Infection microenvironment-activated core-shell nanoassemblies for photothermal/chemodynamic synergistic wound therapy and multimodal imaging | |
US10172361B2 (en) | Doped metal oxide nanoparticles of and uses thereof | |
Liang et al. | Near-infrared laser-controlled nitric oxide-releasing gold nanostar/hollow polydopamine Janus nanoparticles for synergistic elimination of methicillin-resistant Staphylococcus aureus and wound healing | |
US20230200395A1 (en) | Antibacterial surface of metal-organic framework-chitosan composite films | |
Sun et al. | Near-infrared triggered antibacterial nanocomposite membrane containing upconversion nanoparticles | |
Ran et al. | Surface decoration of black phosphorus nanosheets to generate oxygen and release 1 O 2 for photodynamic killing of bacteria | |
US20160312175A1 (en) | Cell coating method using compound comprising gallate group and lanthanoid metal salt or transition metal salt | |
Chu et al. | Silica-supported near-infrared carbon dots and bicarbonate nanoplatform for triple synergistic sterilization and wound healing promotion therapy | |
WO2019121946A1 (en) | Zwitterionic pillararene derivative | |
Hosseini et al. | Facile post modification synthesis of copper-doped mesoporous bioactive glass with high antibacterial performance to fight bone infection | |
CN109125737B (zh) | 负载前体药物的介孔纳米钌系统及制备和在制备治疗耐药细菌感染药物中的应用 | |
Fasiku et al. | Free radical-releasing systems for targeting biofilms | |
CN113134012A (zh) | 一种CaO2/Fe3O4@OA纳米复合物及其制备方法与应用 | |
Yang et al. | A biofilm microenvironment-responsive one-for-all bactericidal nanoplatform for photothermal-augmented multimodal synergistic therapy of pathogenic bacterial biofilm infection | |
Zong et al. | Enhanced eradication of Enterococcus faecalis biofilms by quaternized chitosan-coated upconversion nanoparticles for photodynamic therapy in persistent endodontic infections | |
Li et al. | Photosensitizer doped zeolitic imidazolate framework-8 nanocomposites for combined antibacterial therapy to overcome methicillin-resistant Staphylococcus aureus (MRSA) | |
CN105963697B (zh) | 基于荧光共轭聚合物与上转换纳米材料的复合抗菌剂及其使用方法 | |
CN113041348B (zh) | 具有一氧化氮/光动力协同抗菌、抗炎作用的纳米复合体系及其制备方法与应用 | |
Zhu et al. | A doxorubicin and siRNA coloaded nanolamellar hydroxyapatite/PLGA electrospun scaffold as a safe antitumor drug delivery system | |
CN114870034B (zh) | 一种具备高效抗感染能力的基因转染纳米材料及其制备 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |